226 related articles for article (PubMed ID: 34154331)
1. Immunotherapy in the treatment of non-small cell lung cancer.
Bílek O; Bořilová S; Grell P; Kiss I
Klin Onkol; 2021; 34(Supplementum 1):54-64. PubMed ID: 34154331
[TBL] [Abstract][Full Text] [Related]
2. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
3. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
Cetin B; Bilgetekin İ; Ozet A
Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
[TBL] [Abstract][Full Text] [Related]
4. Advances in immunotherapy for non-small cell lung cancer.
Reckamp KL
Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
7. Principles of Immunotherapy in Non-Small Cell Lung Cancer.
Hsu ML; Naidoo J
Thorac Surg Clin; 2020 May; 30(2):187-198. PubMed ID: 32327177
[TBL] [Abstract][Full Text] [Related]
8. [First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Peng X; Zhou Q
Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):924-930. PubMed ID: 30591101
[TBL] [Abstract][Full Text] [Related]
9. [Non-small cell lung cancer: news from immunotherapy].
Reinmuth N; Heigener DF; Reck M
Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
[TBL] [Abstract][Full Text] [Related]
10. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
12. Updates on immunotherapy in non-small cell lung cancer.
Shimanovsky A; Dasanu CA
Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
[TBL] [Abstract][Full Text] [Related]
13. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Qiao M; Jiang T; Ren S; Zhou C
Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
[TBL] [Abstract][Full Text] [Related]
14. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
Fu MJ; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
16. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
17. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
18. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]